Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
-
Published:2023-05-23
Issue:11
Volume:24
Page:9168
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Zhu Yuezhi1, Tan Jen Kit1ORCID, Wong Sok Kuan2ORCID, Goon Jo Aan1ORCID
Affiliation:
1. Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia 2. Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health problem that affects people even at young ages due to unhealthy lifestyles. Without intervention, NAFLD will develop into nonalcoholic steatohepatitis (NASH) and eventually liver cirrhosis and hepatocellular carcinoma. Although lifestyle interventions are therapeutic, effective implementation remains challenging. In the efforts to establish effective treatment for NAFLD/NASH, microRNA (miRNA)-based therapies began to evolve in the last decade. Therefore, this systematic review aims to summarize current knowledge on the promising miRNA-based approaches in NAFLD/NASH therapies. A current systematic evaluation and a meta-analysis were conducted according to the PRISMA statement. In addition, a comprehensive exploration of PubMed, Cochrane, and Scopus databases was conducted to perform article searches. A total of 56 different miRNAs were reported as potential therapeutic agents in these studies. miRNA-34a antagonist/inhibitor was found to be the most studied variant (n = 7), and it significantly improved the hepatic total cholesterol, total triglyceride, Aspartate Aminotransferase (AST), and Alanine Transaminase (ALT) levels based on a meta-analysis. The biological processes mediated by these miRNAs involved hepatic fat accumulation, inflammation, and fibrosis. miRNAs have shown enormous therapeutic potential in the management of NAFLD/NASH, wherein miRNA-34a antagonist has been found to be an exceptional potential agent for the treatment of NAFLD/NASH.
Funder
UNIVERSITI KEBANGSAAN MALAYSIA HEZE HUIREN CHINESE MEDICINE HOSPITAL
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference136 articles.
1. Mechanisms of NAFLD development and therapeutic strategies;Friedman;Nat. Med.,2018 2. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018 3. Association between Non Alcoholic Fatty Liver Disease and Severity of Coronary Artery Disease in Patients Aged 45 Years and Below with Acute Coronary Syndrome;Eissa;J. Clin. Diagn. Res.,2021 4. Chin, K.Y., Ekeuku, S.O., Chew, D., and Trias, A. (2023). Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review. Nutrients, 15. 5. Pulido, M.R., Diaz-Ruiz, A., Jiménez-Gómez, Y., Garcia-Navarro, S., Gracia-Navarro, F., Tinahones, F., López-Miranda, J., Frühbeck, G., Vázquez-Martínez, R., and Malagón, M.M. (2011). Rab18 dynamics in adipocytes in relation to lipogenesis, lipolysis and obesity. PLoS ONE, 6.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|